Joulaei, Hassan et al. 2014. “The Diminishing Trend of β-Thalassemia in Southern Iran from 1997 to 2011: The Impact of Preventive Strategies.” Hemoglobin 38(1): 19–23.

Kim, Daniel et al. 2011. “Rapid Monitoring of Iron‐chelating Therapy in Thalassemia Major by a New Cardiovascular MR Measure: The Reduced Transverse Relaxation Rate.” NMR in Biomedicine 24(7): 771–77.

Persons, Derek A. 2010. “Targeting β-Thalassaemia.” Nature 467(7313): 277–78.

Mobarra, Naser et al. 2016. “A Review on Iron Chelators in Treatment of Iron Overload Syndromes.” International journal of hematology-oncology and stem cell research 10(4): 239.

Poggiali, E., Cassinerio, E., Zanaboni, L. and Cappellini, M.D., 2012. An update on iron chelation therapy. Blood Transfusion, 10(4), p.411.

Bruin, Gerard J M et al. 2008. “Pharmacokinetics, Distribution, Metabolism, and Excretion of Deferasirox and Its Iron Complex in Rats.” Drug metabolism and disposition 36(12): 2523–38.

Haenisch, S et al. 2007. “Influence of Polymorphisms of ABCB1 and ABCC2 on MRNA and Protein Expression in Normal and Cancerous Kidney Cortex.” The pharmacogenomics journal 7(1): 56–65.

Porter, D., & Taher, J. , 2023. (n.d.). 4 TH EDITION (Version 2.0) SSAEMIA

Lee, Ji Won et al. 2013. “Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent.” PLoS One 8(5): e64114.

Braga, Caroline C B et al. 2017. “Deferasirox Associated with Liver Failure and Death in a Sickle Cell Anemia Patient Homozygous for The− 1774delG Polymorphism in the Abcc2 Gene.” Clinical Case Reports 5(8): 1218.

Cao, Kangna et al. 2020. “ABCC2 c.-24 C> T Single-Nucleotide Polymorphism Was Associated with the Pharmacokinetic Variability of Deferasirox in Chinese Subjects.” European Journal of Clinical Pharmacology 76: 51–59.

Marano, M et al. 2016. “Deferasirox-Induced Serious Adverse Reaction in a Pediatric Patient: Pharmacokinetic and Pharmacogenetic Analysis.” European journal of clinical pharmacology 72: 247–48.

Hartung, Thomas. 2009. “Toxicology for the Twenty-First Century.” Nature 460(7252): 208–12.

Vuda, Madhusudanarao, and Ashwin Kamath. 2016. “Drug Induced Mitochondrial Dysfunction: Mechanisms and Adverse Clinical Consequences.” Mitochondrion 31: 63–74.

Díaz-García, Juan Daniel et al. 2014. “Deferasirox Nephrotoxicity—the Knowns and Unknowns.” Nature reviews nephrology 10(10): 574–86.

Bagnasco, SERENA, DAVID Good, ROBERT Balaban, and MAURICE Burg. 1985. “Lactate Production in Isolated Segments of the Rat Nephron.” American Journal of Physiology-Renal Physiology 248(4): F522–26.

Xu, Wenjing, Tomasa Barrientos, and Nancy C Andrews. 2013. “Iron and Copper in Mitochondrial Diseases.” Cell metabolism 17(3): 319–28.

Dixon, Scott J et al. 2012. “Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death.” cell 149(5): 1060–72.

Poli, Giuseppe. 2000. “Pathogenesis of Liver Fibrosis: Role of Oxidative Stress.” Molecular aspects of medicine 21(3): 49–98.

Jensen, Peter D et al. 2003. “Relationship between Hepatocellular Injury and Transfusional Iron Overload Prior to and during Iron Chelation with Desferrioxamine: A Study in Adult Patients with Acquired Anemias.” Blood, The Journal of the American Society of Hematology 101(1): 91–96.